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Sir,
With the recent publication of the MERTH study [1],
trimethoprim/sulfamethoxazole (SXT) monotherapy will be used
increasingly in the treatment of melioidosis during the eradication
phase, and possibly as the only treatment for some mild infections.
It is therefore important to know the prevalence of SXT resistance
in Burkholderia pseudomallei. This is difﬁcult to test in vitro, with
disc diffusion testing overestimating resistance, and indistinct end-
points in all methods [2]. Even using the Etest method to estimate
the minimum inhibitory concentration (MIC), SXT resistance rates
as high as 24% in a year have occasionally been reported from
Thailand [3]. Recent data from Northern Australia published in this
journal [4] are consistent with our own experience in Southeast
Table 1
Source of isolates.
Laos PDR Cambodia
Blood culture 240 31
Respiratory 126 2
Pus/swab 228 115
Fluid 26 1
Total 620 149
Asia and suggest that true resistance to SXT in B. pseudomallei is
actually very rare.
As our own experience indicated a substantially lower preva-
lence of SXT resistance than the literature suggests, we reviewed
routine data from our diagnostic laboratories in Laos (February
2003 to October 2012) and Cambodia (February 2006 to December
2012). Etest (bioMérieux, Basingstoke, UK) was performed accord-
ing to the manufacturer’s instructions on all isolates in Vientiane
(Laos) and on all isolates that appeared non-susceptible by disc dif-
fusion testing [Clinical and Laboratory Standards Institute (CLSI)
M02-A11 method; zone diameter < 16 mm]  in Siem Reap (Cambo-
dia), as previously recommended [3]. The sources of the strains
tested are shown in Table 1.
Of 769 sequential isolates, 99.2% (615/620) from Laos and 100%
(149/149) from Cambodia were classiﬁed as susceptible to SXT
according to CLSI criteria (trimethoprim MIC  ≤ 2 mg/L). Three iso-
lates had a trimethoprim MIC  of 3 mg/L and two isolates had a
trimethoprim MIC  of 4 mg/L. The range of MICs is shown in Fig. 1.
Fig. 1. Distribution of trimethoprim/sulfamethoxazole (co-trimoxazole) Etest
minimum inhibitory concentrations (MICs) of clinical isolates of Burkholderia pseu-
domallei from (a) Laos and (b) Cambodia.
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This conﬁrms that primary resistance of B. pseudomallei to SXT
is extremely uncommon and should rarely be a contraindication
to SXT monotherapy. These results from Vientiane and Siem Reap
closely mirror those of Crowe et al. in Darwin [4]. Although the
CLSI currently only recommends broth microdilution testing for B.
pseudomallei [5], many years of experience in melioidosis-endemic
areas suggests that disc diffusion testing is reliable for all agents
except SXT, for which Etest gives acceptable results. We  think that
the misleading data in the literature are due to the difﬁculty of
interpreting endpoints in testing susceptibility of B. pseudomallei to
SXT. We  tried to follow the manufacturer’s instructions and read the
Etest at 80% inhibition, but this is a somewhat subjective endpoint.
However, the really important thing that remains to be established
is whether SXT MICs can predict the outcome of SXT monotherapy
in melioidosis.
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Carbapenem-resistant Enterobacter gergoviae
harbouring blaKPC-2 in Brazil
Sir,
Worldwide, Klebsiella pneumoniae carbapenemase (KPC) detec-
tion has been extensively reported every year, and the detection
of new species capable of producing this enzyme is of great con-
cern. KPC production is currently the main mechanism of resistance
to carbapenems in Enterobacteriaceae strains [1]. In Brazil, reports
of new species carrying the blaKPC gene have been made in differ-
ent regions [2]. However, there are rare reports of KPC-producing
Enterobacter gergoviae strains; as far as we are aware, there are only
two reports, both in the USA [3,4].
During routine bacteriological diagnosis in a public teaching
hospital in Recife (Brazil), a bacterial isolate identiﬁed as Enterobac-
ter spp. (named EG2) was  selected. This isolate was derived from
blood of a patient hospitalised in the intensive care unit (ICU). The
patient was  hospitalised in February 2008 with hepatic failure. Dur-
ing their hospital stay, the patient received piperacillin/tazobactam
(TZP) [500 mg  every 6 h (q6 h)] empirically for 2 days. After that,
therapy was changed to imipenem (250 mg  q6 h). Ten days later
the patient died. On the same day, blood samples showed a
carbapenem-resistant Enterobacter spp. isolate. Conﬁrmation of the
isolate identity by 16S ribosomal DNA sequencing revealed an E.
gergoviae isolate. This isolate was used for further analyses.
Minimum inhibitory concentrations (MICs) were determined by
broth microdilution according to Clinical and Laboratory Standards
Institute (CLSI) 2013 guidelines (M100-S23). Molecular analyses
were performed through sequencing after speciﬁc PCR for blaKPC,
for the most common -lactamase genes (blaCTX-M, blaTEM and
blaSHV) and the class 1 integron variable region. Furthermore, the
genetic environment of the blaKPC-2 gene was  analysed by speciﬁc
PCR for the region between ISKpn7  and blaKPC, according to Cuzon
et al. [1].
Plasmid DNA was obtained by a standard protocol and
was used to transform Escherichia coli DH5 chemocompetent
cells. Transformant cells were selected on Mueller–Hinton agar
containing 2 g/mL imipenem and 50 g/mL ticarcillin. Plasmid
typing was  performed by PCR-based replicon typing (PBRT) as pre-
viously described by Carattoli et al. [5].
Results of susceptibility assays showed that isolate EG2 was
multidrug-resistant (Table 1). Isolate EG2 harboured the blaKPC-2,
blaCTX-M-15, blaSHV-5 and blaTEM-1 genes (Table 1). Moreover, the
dfrA22 gene, which confers resistance to trimethoprim, was present
in the variable region of a class 1 integron. Plasmid analysis showed
that EG2 had 133, 65, 25 and 2 kb plasmids. The presence of blaKPC-2,
blaCTX-M-15 and blaSHV-5 genes was conﬁrmed by PCR in transfor-
mant recipient cells, named T-EG2. Analysis of the plasmid proﬁle
from donor and recipient cells showed that they shared only a
